Iodine-125 transperineal prostate brachytherapy with preplanning technique: Pre and post-implant dosimetry results analysis;Curiethérapie prostatique transpérinéale par iode 125 avec dosimétrie prévisionnelle: Analyse des résultats dosimétriques pré- et post-implantation

Cancer/Radiotherapie

Volumn 7, Issue 2, 2003, Pages 90-99

  Simonian Sauve, M ^a   Smart, C ^a   Mailleux, H ^a   Rosello, R ^a   Bladou, F ^b   Salem, N ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

Author keywords

Dosimetry; Iodine 125; Prostate brachytherapy

Indexed keywords

IODINE 125;

ARTICLE; BRACHYTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; CONTROLLED STUDY; HISTOGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; PERINEUM; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT PLANNING;

BRACHYTHERAPY; DOSE FRACTIONATION; HUMANS; IODINE RADIOISOTOPES; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SOFTWARE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0038416089     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1278-3218(02)00277-9     Document Type: Article

References (56)

1. Ash D, Flynn A, Batterman J, De Reijke T, Lavagnini P, Blank L. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315-21.
2. Badiozamani KR, Wallner K, Cavanagh W, Blasco J. Comparability of CT-based and TRUS-based prostate volumes. Int J Radiat Oncol Biol Phys 1999;43:375-8.
3. Batterman J. I-125 implantation for localised prostate cancer: the Utrecht University experience. Radiother Oncol 2000;57:269-72.
4. Benoit RM, Naslund MJ, Cohen JK. Complications after prostate brachytherapy in the Medicare population. Urology 2000;55:91-6.
5. Beyer DC, Brachman DG. Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy. Radiother Oncol 2000;57:263-7.
6. Bice WS, Prestidge BR, Prete JJ, Duhois DF. Clinical impact of implementing the recommendations of AAPM Task Group 43 on Permanent Prostate Brachytherapy using I-125. Int J Radiat Oncol Biol Phys 1998;40:1237-41.
7. Bice WS, Prestidge BR, Grimm PD, Friedland JL, Feygelman V, Roach MIII, et al. Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998;41:921-7.
8. Bice WS, Prestidge BR, Sarosdy MF. Sector analysis of prostate implants. Med Phys 2001;28:2561-7.
9. Blasko JC. Workshop: "Permanent Transperineal Ultrasound guided Brachytherapy in the management of Localized Prostate Cancer", Seattle 1998.
10. Brinkman DH. "Automated seed localization from CT data sets of the prostate". Med Phys 1998;25:1667-72.
11. Butler WM, Merrick GS, Lief JH, Dorsey AT. Comparison of seed loading approaches in prostate brachytherapy. Med Phys 2000;27:381-92.
12. Chauveinc L, Salem N, Pommier P, Peiffert D, Guerif S, Hannoun-Levy JM, et al. Brachytherapy of the prostatic cancer by interstitial permanent implantation of iodine. Cancer Radiother 2002;125(6):112-5.
13. Dubois DF, Prestidge BR, Hotchkiss LA, Bice WS, Prete JJ. Source localization following permanent transperineal prostate interstitial brachytherapy using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1997;39:1037-41.
14. Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:119-24.
15. Grimm PD, Blasco JC, Ragde H. Ultrasound-guided transperineal implantation of iodine 125 and palladium 103 for the treatment of early-stage prostate cancer. Atlas of the urologic clinics of North America 1994;2:113-25.
16. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125) I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:31-40.
17. Jones S, Wallner K, Merrick G, Corriveau J, Sutlief S, True L, et al. Clinical correlates of high intraprostatic brachytherapy dose volumes. Int J Radiat Oncol Biol Phys 2002;53:328-33.
18. Kubo HD, Coursey BM, Hanson WF, Kline RW, Seltzer SM, Shuping RE, et al. Report of the Ad Hoc Committee of the AAPM Radiation Therapy Committee on I-125 sealed source dosimetry. Int J Radiat Oncol Biol Phys 1998;40:697-702.
19. Lee WR, DeGuzman AF, Bare RL, Marshall MG, McCullough DL. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys 2000;46:83-8.
20. Luse RW, Blasko J, Grimm P. A method for implementing the american association of physicists in medecine task group-43 dosimetry recommendations for 125I transperineal prostate seed implants on commercial treatment planning system. Int J Radiat Oncol Biol Phys 1997;37:737-41.
21. Merrick GS, Butler WM, Dorsey AT, Walbert HL. Influence of timing on the dosimetric analysis of transperineal ultrasound-guided, prostatic conformal brachytherapy. Radiat Oncol Investig 1998;6:182-90.
22. Merrick GS, Butler WM, Dorsey AT, Lief JH. Potential role of various dosimetric quality indicators in prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999;44:717-24.
23. Merrick GS, Butler WM, Dorsey AT, Lief JH. The dependance of prostate postimplant dosimetric quality on CT volume determination. Int J Radiat Oncol Biol Phys 1999;44:1111-7.
24. Merrick GS, Butler WM, Galbreath RW, Lief JH. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 2001;51:41-8.
25. Moerland MA, Van Der Laarse R, Luthmann RW, Wijrdeman HK, Battermann JJ. The combined use of the natural and the cumulative dose-volume histograms in planning and evaluation of permanent prostatic seed implants. Radiother Oncol 2000;57:279-84.
26. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-99.
27. Nag S, Bice W, DeWyngaert K, Prestidge B, Stock R, Yu Y. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000;46:221-30.
28. Narayana V, Roberson PL, Pu AT, Sandler H, Winfield PW, McLaughlin PW. Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants. Int J Radiat Oncol Biol Phys 1997;37:1181-5.
29. Narayana V, Roberson PL, Winfield PW, McLaughlin PW. Impact of ultrasound and computed tomography volume registration on evaluation of permanent prostate implants. Int J Radiat Oncol Biol Phys 1997;39:341-6.
30. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group N° 43. Med Phys 1995;22:209-34.
31. Nath R, Anderson LL, Meli J, Olch AJ, Stitt JA, Williamson JF. Code of practice for brachytherapy physics: Report of the AAPM Radiation Therapy Committee Task Group N° 56. Med Phys 1997;24:1557-98.
32. Van Den Ouden D, Hop WC, Kranse R, Schroder FH. Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br J Urol 1997;79:203-11.
33. Potters L, Cao Y, Calugaru E, Torre T, Fearn P, Wang XH. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001;50:605-14.
34. Ragde H, Grado GL, Nadir B, Elgamal AA. Modern prostate brachytherapy. CA Cancer J Clin 2000;50:380-93.
35. Roberson PL, Narayana V, Winfield R, McLaughin PW. Source placement error for permanent implant of the prostate. Med Phys 1997;24:251-7.
36. Robert JA, David G, Kenneth AL, Robert DH. Prostate seed implant quality assessment using MR and CT image fusion. Int J Radiat Oncol Biol Phys 1999;43:67-72.
37. Van't Riet A, Mak CA, Moerland MA, Elders LH, Van der Zee W. A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate. Int J Radiat Oncol Biol Phys 1997137:731-6.
38. Seltzer SM, Lamperti PJ, Loevinger R, Soares CG, Weaver JT. New NIST air-kerma strength standards for I-125 and Pd-103 brachytherapy seeds. Med Phys 1998;25:170.
39. Snyder KM, Stock RG, Hong SM, Lo YC, Stone NN. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001;50:335-41.
40. Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998;41:101-8.
41. Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001;165:436-9.
42. Stone NN, Stock RG, DeWyngaert JK, Tabert A. Prostate brachytherapy: improvements in prostate volume measurements and dose distribution using ultrasound guided implantation and three-dimensional dosimetry. Radiat Oncol Investig 1995;3:185-95.
43. Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol 2002;41:427-33.
44. Stone NN, Stock RG. Permanent seed implantation for localized adenocarcinoma of the prostate. Curr Urol Rep 2002;3:201-6.
45. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996;14:449-53.
46. Waterman F, Yue N, Corn BW, Dicker AP. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on postimplant dosimetry: an analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 1998;41:1069-77.
47. Williamson JF, Coursey BM, DeWerd LA, Hanson WF, Nath R, Ibbott G. Guidance to users of Nycomed Amersham and North American Scientific, Inc, I-125 interstitial Sources: dosimetry and calibration changes: recommendations of the AAPM Radiation Therapy Committee Ad Hoc Subcommittee on low-energy seed dosimetry. Med Phys 1999;26:570-3.
48. Willins J, Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1997;39:347-53.
49. Willins J, Wallner K. Time-dependent changes in CT-based dosimetry of I-125 prostate brachytherapy. Radiat Oncol Investig 1998;6:157-60.
50. Wu A, Lee CC, Johnson M, Brown D, Benoit R, Miler R, et al. A new power law for determination of total 125 I seed activity for ultrasound-guided prostate implants: clinical evaluations. Int J Radiat Oncol Biol Phys 2000;47:1397-403.
51. Wuu CS, Ennis RD, Schiff PB, Lee EK, Zaider M. Dosimetric and volumetric criteria for selecting a source activity and a source type (125 I or 103 Pd) in the presence of irregular seed placement in permanent prostate implant. Int J Radiat Oncol Biol Phys 2000;47:815-20.
52. Yu Y, Anderson LL, Mellenberg DE, Nath R, Schell MC, Waterman F, et al. Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medecine Task Group No 64. Med Phys 1999;26:2054-76.
53. Yue N, Dicker AP, Corn BW, Nath R, Waterman F. A dynamic model for the estimation of optimum timing of computed tomography scan for dose evaluation of 125 I or 103 Pd seed implant of prostate. Int J Radiat Oncol Biol Phys 1999;43:447-54.
54. Yue N, Dicker AP, Nath R, Waterman F. The impact of edema on planning 125 I or 103 Pd prostate implants. Med Phys 1999;25:763-7.
55. Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000;47:1261-6.
56. Zhe C, Ning Y, Xiaohong W. Kenneth BR, Richard P, Ravinder N. Dosimetric effects of edema in permanent prostate seed implants: a rigorus solution. Int J Radiat Oncol Biol Phys 2000;47:1405-19.